Federated Hermes, Inc. Nuvalent, Inc. Transaction History

Federated Hermes, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$39.12 - $49.85 $2,268 - $2,891	-58 Reduced 57.43%	43 $1,000
Q2 2023 Aug 14, 2023	SELL	$23.58 - $44.68 $6,885 - $13,046	-292 Reduced 74.3%	101 $4,000
Q1 2023 May 08, 2023	BUY	$25.42 - $33.52 $7,219 - $9,519	284 Added 260.55%	393 $10,000
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $2,012 - $3,964	109 New	109 $3,000

210

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.08B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.